Jeffrey Zucker brings more than 25 years of experience in clinical research operations across sites, sponsors, CROs, and technology partners. Trained as a psychotherapist with a specialty in industrial dynamics, he combines deep behavioral insight with a career spent optimizing feasibility, patient recruitment, rater quality, and site performance across neuroscience and complex clinical trial environments.
Throughout his career, Jeff has led global feasibility, site management, and trial optimization teams at organizations including Worldwide Clinical Trials, ICON, INC Research, and Eli Lilly. His work spans nearly every therapeutic area and study phase, with a notable focus on CNS including Depression, Anxiety Disorders, Alzheimer’s, Schizophrenia, and rare diseases.
Jeff’s multi-lens industry background including operations, rater-dependent study oversight, investigator relations, and patient recruitment strategy, gives him a practical, systems-level approach to elevating rater reliability and operational readiness. As Tekton’s Chief Development Officer and CNS Consultant, he supports teams in strengthening scale administration quality, site consistency, and operational performance to ensure reliable, high-integrity data for CNS trials.